6 julio 2015
Based on new analyses conducted by the drug manufacturer, an advantage can be determined in two instead of only one patient group for the use of Fingolimod in relapsing remitting multiple sclerosis. There are now indications instead of a hint.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/m7pluGenR3s/150706103829.htm
